AMY JACKSON: Open Payments
NPI 1972866085 · MUNCIE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$792 in 32 payments from 15 companies in 2025. Trend: 2023 $290 · 2024 $555 · 2025 $792
Food & beverage: $792
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 11 | $325 |
| Luye Pharma (USA) Ltd. | 3 | $139 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Novo Nordisk Inc | 2 | $41 |
| Neos Therapeutics, LP | 1 | $22 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
| Amgen Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $18 |
Products named: ARISTADA, ERZOFRI EXTENDED-RELEASE, LYBALVI, UZEDY, Ozempic, REXULTI, Adzenys XR-ODT, INGREZZA.
Industry payments across IN — which companies pay providers there.
